A Phase 1 interventional study of OTX-TIC in Ocular Hypertension and Open Angle Glaucoma, sponsored by Ocular Therapeutix, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Ocular Therapeutix, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 246th largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2018, is one of 19 in phase 1, and was the 228th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 16 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Ocular Therapeutix, Inc. has 4 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
This is a prospective, multicenter, open label study, to evaluate the safety, tolerability and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or ocular hypertension. The subjects will be followed for approximately 7 months (one-month washout and 6 months follow-up after injected of the OTX-TIC implant).
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 19 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 µg (formulation1) implant
Drug: OTX-TIC
26 µg (formulation1) implant
Drug: OTX-TIC
15 µg (formulation 2) implant
Drug: OTX-TIC
5 µg (formulation 3) implant
Drug: OTX-TIC
OTX-TIC implant is injection in the anterior chamber of the eye
Ocular Treatment Emergent Adverse Events
All adverse events will be captured throughout the study
Time frame: Through study completion, 6 months
Efficacy Outcome
IOP measurements at 8 am
Time frame: Diurnal IOP [12 Week Visit]
| Milestone | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 |
|---|---|---|---|---|
| Started | 5 | 4 | 5 | 5 |
| Completed | 5 | 4 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
All adverse events will be captured throughout the study
| Number of Treatment-Emergent Events | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 |
|---|---|---|---|---|
| Ocular Treatment Emergent Adverse Events | 9 | 7 | 9 | 1 |
IOP measurements at 8 am
| mmHg mean IOP change at wk12 from bln | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 |
|---|---|---|---|---|
| Efficacy Outcome | -5.6 ± 2.58 | -7.0 ± 3.27 | -3.0 ± 14.4 | -7.4 ± 4.76 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-TIC-Cohort 1 | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| OTX-TIC-Cohort 2 | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| OTX-TIC-Cohort 3 | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| OTX-TIC-Cohort 4 | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 |
|---|---|---|---|---|
| Eye DisordersEye disorders | 3/5 | 2/4 | 2/5 | 1/5 |
| InvestigationsEye disorders | 0/5 | 0/4 | 3/5 | 0/5 |
| Uncoded TermsEye disorders | 0/5 | 0/4 | 2/5 | 0/5 |
| Congenital, familial and genetic disordersEye disorders | 1/5 | 0/4 | 0/5 | 0/5 |
| Age, Categorical(Participants) | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 2 | 2 | 5 |
| >=65 years | 5 | 3 | 3 | 3 | 14 |
| Sex: Female, Male(Participants) | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 4 | 4 | 15 |
| Male | 2 | 0 | 1 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 4 | 6 |
| Not Hispanic or Latino | 5 | 3 | 4 | 1 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 3 | 0 | 5 |
| White | 5 | 2 | 2 | 5 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | OTX-TIC-Cohort 1 | OTX-TIC-Cohort 2 | OTX-TIC-Cohort 3 | OTX-TIC-Cohort 4 | Total |
|---|---|---|---|---|---|
| United States | 5 | 4 | 5 | 5 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in May 2021, 36 months.
Results were first posted in Oct 2024, 3 years 4 months after primary completion.
Of 17 phase 1 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.